Severe immune thrombocytopenia (ITP) following SARS-CoV-2 mRNA vaccine in a girl on immunosuppressive treatment and in prolonged stable phase of ITP.
Rare cases of immune thrombocytopenia (ITP) occurring after SARS-CoV-2 mRNA vaccines have recently reached public attention. It has been reported in patients with previous ITP or other autoimmune diseases and in individuals with an apparent negative past medical history. The management and the outc...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2022-01-01
|
| Series: | Mediterranean Journal of Hematology and Infectious Diseases |
| Subjects: | |
| Online Access: | https://mjhid.org/index.php/mjhid/article/view/4803 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850106173370400768 |
|---|---|
| author | SIMONA BIANCHI ALESSIA ANGI MAURO PASSUCCI GIOVANNA PALUMBO ERMINIA BALDACCI ANNA MARIA TESTI |
| author_facet | SIMONA BIANCHI ALESSIA ANGI MAURO PASSUCCI GIOVANNA PALUMBO ERMINIA BALDACCI ANNA MARIA TESTI |
| author_sort | SIMONA BIANCHI |
| collection | DOAJ |
| description | Rare cases of immune thrombocytopenia (ITP) occurring after SARS-CoV-2 mRNA vaccines have recently reached public attention. It has been reported in patients with previous ITP or other autoimmune diseases and in individuals with an apparent negative past medical history. The management and the outcome of these cases are still not well investigated and reported in the medical literature. A 23-year-old female with a past medical history of ITP, in stable complete remission for 3 years and on mycophenolate treatment received SARS-CoV-2 mRNA vaccine. She presented severe ITP recurrence with hemorrhagic symptoms after the second vaccine dose. A combined treatment with high-dose immunoglobulin and prednisone was successfully administered with a full recovery of platelet count. The patient remains in ITP remission and on mycophenolate therapy, five months later. At our Center, none of the other 76 adult “fragile patients” with ITP on immunosuppressive treatment who had received the SARS-CoV-2 mRNA vaccine, developed such a severe thrombocytopenic recurrence. Follow-up of large cohorts of patients receiving mRNA vaccine will answer the question as to whether it increases the risk of autoimmune conditions. So far, the benefits of the vaccination largely outweigh the risk of infection in these patients. |
| format | Article |
| id | doaj-art-c9adc0e3cd844998b3e4e2680fb5757e |
| institution | OA Journals |
| issn | 2035-3006 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | PAGEPress Publications |
| record_format | Article |
| series | Mediterranean Journal of Hematology and Infectious Diseases |
| spelling | doaj-art-c9adc0e3cd844998b3e4e2680fb5757e2025-08-20T02:38:53ZengPAGEPress PublicationsMediterranean Journal of Hematology and Infectious Diseases2035-30062022-01-0114110.4084/MJHID.2022.011Severe immune thrombocytopenia (ITP) following SARS-CoV-2 mRNA vaccine in a girl on immunosuppressive treatment and in prolonged stable phase of ITP.SIMONA BIANCHI0ALESSIA ANGIMAURO PASSUCCIGIOVANNA PALUMBOERMINIA BALDACCIANNA MARIA TESTIa:1:{s:5:"en_US";s:91:"DPT OF TRANSLATIONAL AND PRECISION MEDICINE, HAEMATOLOGY SECTION, SAPIENZA UNIVERSITY, ROME";}Rare cases of immune thrombocytopenia (ITP) occurring after SARS-CoV-2 mRNA vaccines have recently reached public attention. It has been reported in patients with previous ITP or other autoimmune diseases and in individuals with an apparent negative past medical history. The management and the outcome of these cases are still not well investigated and reported in the medical literature. A 23-year-old female with a past medical history of ITP, in stable complete remission for 3 years and on mycophenolate treatment received SARS-CoV-2 mRNA vaccine. She presented severe ITP recurrence with hemorrhagic symptoms after the second vaccine dose. A combined treatment with high-dose immunoglobulin and prednisone was successfully administered with a full recovery of platelet count. The patient remains in ITP remission and on mycophenolate therapy, five months later. At our Center, none of the other 76 adult “fragile patients” with ITP on immunosuppressive treatment who had received the SARS-CoV-2 mRNA vaccine, developed such a severe thrombocytopenic recurrence. Follow-up of large cohorts of patients receiving mRNA vaccine will answer the question as to whether it increases the risk of autoimmune conditions. So far, the benefits of the vaccination largely outweigh the risk of infection in these patients.https://mjhid.org/index.php/mjhid/article/view/4803immune thrombocytopeniaSARS-CoV-2 mRNA vaccineadverse eventimmunosuppressive therapy |
| spellingShingle | SIMONA BIANCHI ALESSIA ANGI MAURO PASSUCCI GIOVANNA PALUMBO ERMINIA BALDACCI ANNA MARIA TESTI Severe immune thrombocytopenia (ITP) following SARS-CoV-2 mRNA vaccine in a girl on immunosuppressive treatment and in prolonged stable phase of ITP. Mediterranean Journal of Hematology and Infectious Diseases immune thrombocytopenia SARS-CoV-2 mRNA vaccine adverse event immunosuppressive therapy |
| title | Severe immune thrombocytopenia (ITP) following SARS-CoV-2 mRNA vaccine in a girl on immunosuppressive treatment and in prolonged stable phase of ITP. |
| title_full | Severe immune thrombocytopenia (ITP) following SARS-CoV-2 mRNA vaccine in a girl on immunosuppressive treatment and in prolonged stable phase of ITP. |
| title_fullStr | Severe immune thrombocytopenia (ITP) following SARS-CoV-2 mRNA vaccine in a girl on immunosuppressive treatment and in prolonged stable phase of ITP. |
| title_full_unstemmed | Severe immune thrombocytopenia (ITP) following SARS-CoV-2 mRNA vaccine in a girl on immunosuppressive treatment and in prolonged stable phase of ITP. |
| title_short | Severe immune thrombocytopenia (ITP) following SARS-CoV-2 mRNA vaccine in a girl on immunosuppressive treatment and in prolonged stable phase of ITP. |
| title_sort | severe immune thrombocytopenia itp following sars cov 2 mrna vaccine in a girl on immunosuppressive treatment and in prolonged stable phase of itp |
| topic | immune thrombocytopenia SARS-CoV-2 mRNA vaccine adverse event immunosuppressive therapy |
| url | https://mjhid.org/index.php/mjhid/article/view/4803 |
| work_keys_str_mv | AT simonabianchi severeimmunethrombocytopeniaitpfollowingsarscov2mrnavaccineinagirlonimmunosuppressivetreatmentandinprolongedstablephaseofitp AT alessiaangi severeimmunethrombocytopeniaitpfollowingsarscov2mrnavaccineinagirlonimmunosuppressivetreatmentandinprolongedstablephaseofitp AT mauropassucci severeimmunethrombocytopeniaitpfollowingsarscov2mrnavaccineinagirlonimmunosuppressivetreatmentandinprolongedstablephaseofitp AT giovannapalumbo severeimmunethrombocytopeniaitpfollowingsarscov2mrnavaccineinagirlonimmunosuppressivetreatmentandinprolongedstablephaseofitp AT erminiabaldacci severeimmunethrombocytopeniaitpfollowingsarscov2mrnavaccineinagirlonimmunosuppressivetreatmentandinprolongedstablephaseofitp AT annamariatesti severeimmunethrombocytopeniaitpfollowingsarscov2mrnavaccineinagirlonimmunosuppressivetreatmentandinprolongedstablephaseofitp |